• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305

Introduction to 2-(Difluoromethoxy)-7-naphthol (CAS No. 1094284-18-0)

2-(Difluoromethoxy)-7-naphthol, identified by the Chemical Abstracts Service Number (CAS No.) 1094284-18-0, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical and biochemical research. This compound, featuring a naphthol core substituted with a difluoromethoxy group, exhibits unique structural and chemical properties that make it a valuable intermediate in the synthesis of various bioactive molecules.

The naphthol moiety, characterized by its hydroxyl group attached to a naphthalene ring, provides a versatile platform for further functionalization. The presence of the difluoromethoxy group introduces electron-withdrawing and electron-donating effects that can modulate the reactivity and binding affinity of the molecule. These features have positioned 2-(Difluoromethoxy)-7-naphthol as a key building block in the development of novel therapeutic agents.

In recent years, there has been growing interest in exploring the pharmacological potential of compounds containing fluoro substituents. Fluorine atoms are known to enhance metabolic stability, binding affinity, and bioavailability of drug candidates. The incorporation of a difluoromethoxy group into a naphthol scaffold leverages these advantages, making 2-(Difluoromethoxy)-7-naphthol a promising candidate for further investigation.

One of the most compelling aspects of 2-(Difluoromethoxy)-7-naphthol is its utility in the synthesis of heterocyclic compounds, which are widely prevalent in biologically active molecules. The naphthol ring can serve as a scaffold for constructing more complex structures, while the difluoromethoxy group provides opportunities for selective modifications. This flexibility has been exploited in several research studies aimed at developing new drugs targeting various diseases.

Recent studies have highlighted the role of 2-(Difluoromethoxy)-7-naphthol in the development of small-molecule inhibitors for enzymes involved in cancer metabolism. For instance, researchers have demonstrated its efficacy in inhibiting key enzymes such as tyrosine kinases and phosphatidylinositol 3-kinase (PI3K), which are crucial in cancer cell proliferation and survival. The unique electronic properties conferred by the difluoromethoxy group have been shown to improve binding interactions with these targets, leading to enhanced inhibitory activity.

Another area where 2-(Difluoromethoxy)-7-naphthol has shown promise is in the field of anti-inflammatory drug discovery. Inflammatory processes are mediated by a complex interplay of signaling pathways and enzymes, many of which are potential targets for therapeutic intervention. The structural features of 2-(Difluoromethoxy)-7-naphthol have been exploited to develop novel inhibitors of cyclooxygenase (COX) and lipoxygenase (LOX), key enzymes involved in inflammation. Preclinical studies have indicated that derivatives of this compound exhibit significant anti-inflammatory effects without notable side effects.

The synthesis of 2-(Difluoromethoxy)-7-naphthol involves multi-step organic transformations that highlight its synthetic utility. The introduction of the difluoromethoxy group typically requires fluorination techniques such as electrophilic aromatic substitution or metal-catalyzed cross-coupling reactions. These synthetic strategies not only showcase the versatility of the compound but also provide insights into modern synthetic methodologies used in pharmaceutical chemistry.

Advances in computational chemistry have further enhanced our understanding of the properties and reactivity of 2-(Difluoromethoxy)-7-naphthol. Molecular modeling studies have revealed detailed insights into its interactions with biological targets, providing a rational basis for designing more effective derivatives. These computational approaches have been instrumental in predicting binding affinities and optimizing lead structures for drug development.

The pharmacokinetic profile of 2-(Difluoromethoxy)-7-naphthol and its derivatives is another critical aspect that has been extensively studied. Fluoro-substituted compounds often exhibit improved pharmacokinetic properties due to their enhanced lipophilicity and metabolic stability. This has made them attractive candidates for oral administration and prolonged therapeutic effects. Investigating these properties helps in designing drugs with better bioavailability and reduced susceptibility to degradation by metabolic enzymes.

In conclusion, 2-(Difluoromethoxy)-7-naphthol (CAS No. 1094284-18-0) represents a significant advancement in pharmaceutical chemistry due to its unique structural features and broad applicability. Its role as an intermediate in synthesizing bioactive molecules, particularly those targeting cancer and inflammation, underscores its importance in drug discovery efforts. As research continues to uncover new therapeutic applications, compounds like 2-(Difluoromethoxy)-7-naphthol will remain at the forefront of medicinal chemistry innovation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)